“Sotrovisab”. This drug contains the “Omicron” strain.

Chulabhorn Royal College recommends getting to know a drug to treat covids called Sotrovimab. Sotrovimab Effective against all strains of COVID-19, including mutant Omicron viruses.

get to know Sotrovimab Drug to treat covids against Omicron strain (B.1.1.529)

Omicron (B.1.1.529), a worrying mutant Variant Of Concern (VOC), which was first reported to be infected with this strain in Africa. Currently, outbreaks of Omicron strains have been found in many regions of the world. Including the infection of the Omicron strain in Thailand.

by virus strain “Omicron” As many as 37 spike protein sites were mutated, and some of these mutations were found to impair the effectiveness of current therapies.

The results of early studies show that a drug called sotrovimab Sotrovimab (VIR-7831) is effective against all strains of COVID-19, including mutant Omicron viruses. It was effective against all mutations in spiny proteins of omikron strains. Although there were 37 mutations in the spiny protein

The inhibition was aimed at the spiny protein. which is part of the virus that binds to the cells in our body And there was a small change in drug sensitivity to a level that the drug was able to inhibit the Omicron strain virus (IC50) equal to 2.7 times that of the normal strain. These simulated virus data show that Sotrovimab (VIR-7831) continued to inactivate the virus in each Omicron mutation at all tested sites.

The experiment also compared the viral inactivation with Sotrovimab (VIR-7831) between the original and Omicron strains and found that the concentration of Sotrovimab used to destroy Omicron was close to that of the original strain.

apart from this It also found data from agencies that referenced and published the results of Sotrovimab and Omicron sensitivity tests support that. Sotrovimab are susceptible to such species while monoclonal Other antibodies have a reduced sensitivity.

For Sotrovimab, it was developed with viral mutations in mind. Sotrovimab has been shown to reduce the risk of serious illness and death in COVID-19 patients, according to trials. with 79 percent of mild to moderate symptoms and effective in stopping the infection from spreading to the lungs.

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Sotrovimab under the trade name Xevudy for use in COVID-19 patients. mild to moderate and those who are at high risk of developing serious illnesses

The goal is to stop the incidence of severe illnesses among those who have been infected with COVID-19. It is useful for people with weakened immune systems. The MHRA recommends taking the drug as soon as possible or within 5 days of onset of illness.



Leave a Reply

Your email address will not be published. Required fields are marked *